P299 Loss-of-response to anti-tumour necrosis factor-α critically depends on treatment duration in patients with Inflammatory Bowel Disease
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.423
Abstract: Inflammatory bowel disease (IBD) is often managed with anti-tumour necrosis factor-α (anti-TNFα) compounds, but only few studies have reported on long-term outcomes. We aimed to determine whether the incidence of loss-of-response decreases with longer treatment… read more here.
Keywords: treatment duration; loss response; loss; anti tnf ... See more keywords
Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels.
Sign Up to like & getrecommendations! Published in 2021 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izab158
Abstract: BACKGROUND In cases of loss of response due to mechanistic failure under antitumor necrosis factor agents, it is recommended to switch to another class of biologics. Two different strategies were compared in patients with inflammatory… read more here.
Keywords: trough levels; response; loss response; group ... See more keywords
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
Sign Up to like & getrecommendations! Published in 2018 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izy171
Abstract: Background We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. Methods Retrospective review (May 2014-December 2016) of a prospectively maintained inflammatory… read more here.
Keywords: inflammatory bowel; loss response; bowel disease; response ... See more keywords
Potential contributors to variation in weight‐loss response to liraglutide
Sign Up to like & getrecommendations! Published in 2023 at "Obesity Reviews"
DOI: 10.1111/obr.13568
Abstract: Obesity treatment requires a chronic state of negative energy balance. Obesity medications can help with this, increasing long‐term dietary compliance by promoting satiety or reducing hunger. However, efficacy and safety of obesity medications vary for… read more here.
Keywords: loss; loss response; obesity medications; weight loss ... See more keywords
Association of SMAD4 loss with response to neoadjuvant chemotherapy with the autophagy inhibitor hydroxychloroquine in patients with pancreatic adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.761
Abstract: 761Background: SMAD4, a tumor suppressor gene, is inactivated or deleted in 60-90% of pancreatic adenocarcinomas (PDA). Loss of SMAD4 allows tumor progression by limiting cell cycle arrest and apop... read more here.
Keywords: response neoadjuvant; loss response; smad4 loss; neoadjuvant chemotherapy ... See more keywords
Establishment of an Individualized Chronotherapy, Autonomic Nervous System, and Variability-Based Dynamic Platform for Overcoming the Loss of Response to Analgesics.
Sign Up to like & getrecommendations! Published in 2021 at "Pain physician"
DOI: 10.36076/ppj.2021/24/243
Abstract: BACKGROUND Control of chronic pain and mainly the partial or complete loss of response to analgesics is a major unmet need. Multiple mechanisms underline the development of tolerance to analgesics in general and specifically to… read more here.
Keywords: system; response analgesics; variability; loss response ... See more keywords